Latest Progress of BuMA Supreme™ released at CIT2015
The 13th China Interventional Therapeutics Conference (CIT) has taken place in Beijing National Conference & Exhibition Center between 19th and 22th March. On 21th March, China hosted its Luncheon Symposium where the topics mainly focused on the late breaking results of BuMA and BuMA Supreme. Next to prof. Patrick W. Serruys, prof. Renu Virmani, prof. Junbo Ge and Dr. Jianping Li,China has invited Key Opinion Leaders (prof. Yong Huo, prof. Huay Cheem Tan, prof. Robaayah Zambahari, prof. Rosli Mohd Ali and prof. Teguh Santoso) from China and south-east Asia to co-chair the session.

During this session, Dr. Jianping Li from Peking University First Hospital shared a systematic overview on endothelium functional healing. A new concept named ‘the window of opportunity hypothesis’ was introduced and discussed in this session. With this presentation, Dr. Jianping Li aimed to clarify the process of endothelium restoration and provide the benefit of BuMA from a perspective of vascular restoration. This concept entails that complete functional endothelial healing is required to prevent late stent thrombosis in the long-term. In order to achieve this, functional endothelium healing need to be achieved within a certain period.

Furthermore, Dr. Jianping Li provided an overview on all BuMA Series clinical trials. PANDA III is a post-market RCT trial where the enrollment has completed in September 2014. The primary endpoint of this trial is 1 year TLD including cardiac death, target vessel MI and clinical driven TLR. One year result is anticipated to confirm the concept ‘the window of opportunity’.

Prof. Renu Virmani and prof. Patrick W. Serruys provided latest information on BuMA Supreme. BuMA Supreme is the 2nd generation DES of China where a platform alteration is made (from 316L to CoCr). Prof. Serruys provided insights and updates on the FIM trial called PIONEER in Europe. This FIM trial is a multi center trial including 13 sites in the Netherlands, Belgium, Spain and Portugal. The first patient enrolment will take place by end of March 2015.

BuMA (1st generation) has been implanted in China (130.000) with superior clinical results. It is considered by Chinese cardiologists as the safest coronary stent presently available on the market, both in terms of success rate of implantation and in terms of long terms acceptance and safety for patients.



Luncheon Symposium CIT 2013
During CIT 2013 on 28th March, Beijing hosted its Luncheon Symposium named: ‘From China to US, how long does it take to reach perfect endothelialization?’. The latest results of OCT analysis of a 12 month comparative study were released. This symposium was chaired by Prof. Bo Yu from 2nd affiliated hospital of Harbin Medical University and Prof. Shubin Qiao from Fuwai hospital CAMS & PUMC.

A follow-up on CIT 2012 compared the results of 3 and 12 months on the endothelialization process between BuMA™ and XIENCE V. Considerable publicity was generated for its unique trial design comparing BuMA™ to XIENCE V and implanting both types of stents in the same lesion, vessel and patient in order to reduce blood vessel variances. Dr. Jingbo Hou from the 2nd affiliated Hospital of Medical University of Harbin has released significant and outstanding 12 month results with BuMA™ reaching superior outcomes in strut coverage. Parameters such as malapposition, protruding and embedding were all significantly better for BuMA™ after 12 month observation. (Click here for more information on this study)

Furthermore, Dr. Renu Virmani from CVPath in U.S revealed her OCT swine coronary analysis comparing BuMA™ with XIENCE V. The design of the study was the same as with human OCT analysis conducted by Jingbo Hou, M.D. In this research, both BuMA™ and XIENCE V showed complete endothelialization in 45 days, and also excellent neointimal coverage even after 14 days. Also, all histological parameters were comparable between BuMA™ and XIENCE V. Finally, OCT analysis has shown accurately measured neointimal thickness with excellent correlation with histology.



Shanghai crown medical instruments Co., Ltd as a subsidiary of AM CROWN HOLDING GROUP,was established in 1999, which set the headquarter in Shanghai and set factories in Hanzhong city,Guangyuan city, …